for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Arbutus Biopharma Corp

ABUS.O

Latest Trade

2.83USD

Change

0.12(+4.24%)

Volume

1,372,706

Today's Range

2.71

 - 

2.85

52 Week Range

2.41

 - 

6.50

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.71
Open
2.71
Volume
1,372,706
3M AVG Volume
207.41
Today's High
2.85
Today's Low
2.71
52 Week High
6.50
52 Week Low
2.41
Shares Out (MIL)
135.27
Market Cap (MIL)
366.58
Forward P/E
-3.08
Dividend (Yield %)
--

Next Event

Q4 2021 Arbutus Biopharma Corp Earnings Release

Latest Developments

More

Arbutus Biopharma Corp - Expect Net Cash Burn To Range From $90 Million To $95 Million In 2022

Arbutus And Qilu Pharmaceutical Enter Licensing Agreement For AB-729

Preliminary Data Shows That Arbutus' Capsid Inhibitor, AB-836 Is Generally Safe And Well-Tolerated And Provides Robust Antiviral Activity

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Arbutus Biopharma Corp

Arbutus Biopharma Corporation is a clinical-stage, biopharmaceutical company. The Company is focused primarily on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple product candidates with distinct mechanisms of action that have the potential to provide a curative regimen for chronic HBV infection. The Company has also initiated a drug discovery and development effort for treating coronaviruses, including COVID-19. The Company’s two lead product candidates are AB-729, its subcutaneously-delivered RNA interference (RNAi) product candidate that suppresses HBsAg expression, and AB-836, the Company’s next-generation oral capsid inhibitor that suppresses HBV DNA replication. AB-729 is in an ongoing Phase Ia/Ib clinical trial and a Phase IIa proof-of-concept clinical trial in collaboration with Assembly Biosciences, Inc.

Industry

Biotechnology & Drugs

Contact Info

701 Veterans Circle

WARMINSTER, PA

18974

United States

+1.267.4690914

http://www.arbutusbio.com/

Executive Leadership

Frank M. Torti

Independent Chairman of the Board

William H. Collier

President, Chief Executive Officer, Director

David C. Hastings

Chief Financial Officer

Elizabeth Howard

Executive Vice President, General Counsel, Chief Compliance Officer and Secretary

Michael Joseph Sofia

Chief Scientific Officer

Key Stats

2.40 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-1.210

2019

-2.890

2020

-1.000

2021(E)

-0.862
Price To Earnings (TTM)
--
Price To Sales (TTM)
36.05
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-51.59
Return on Equity (TTM)
-48.51

Latest News

Latest News

Moderna could be sued over vaccines as court upholds Arbutus patents

Moderna Inc could face a patent infringement lawsuit over its COVID-19 vaccine after a federal appeals court on Wednesday rejected its challenge to patents belonging to Arbutus Biopharma Corp.

Moderna loses appeal challenging Arbutus vaccine patents

A federal appeals court on Wednesday rejected Moderna Inc's bid to invalidate patents belonging to Arbutus Biopharma Corp that could be crucial in the development of future vaccines against COVID-19 and other illnesses.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up